Titan Pharmaceuticals (TTNP)
(Real Time Quote from BATS)
$6.60 USD
+0.15 (2.33%)
Updated May 21, 2024 12:18 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Titan Pharmaceuticals, Inc. [TTNP]
Reports for Purchase
Showing records 41 - 60 ( 113 total )
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Recap - Waiting for May 27th (Expecting Approval)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Recap - Probuphine PDUFA Approaching Feb. 27
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.